GLP-1
LGC announced the acquisition of a majority stake in Toronto Research Chemicals, a leading manufacturer and supplier of synthetic organic bio-chemicals which are used as reference standards, research tools and building blocks by a highly diversified global customer base across the pharmaceutical, applied and research sectors.
The deal has a flexible framework, which will allow for a variety of projects at different stages of development over several years.
Novo Nordisk intends to use the site to support manufacturing of its oral type 2 diabetes treatment that is under review for approval by the U.S. Food and Drug Administration.
Galapagos NV announces its unaudited first half-year results, which are further detailed in its H1 2019 report available on the Galapagos website, www.glpg.com.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
Bridge Biotherapeutics licensed out its BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion. This is the second large deal for fibrotic diseases Boehringer Ingelheim inked since the beginning of the month.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
Galapagos will receive $3.95 billion in upfront cash, as well as a $1.1 billion equity investment from Gilead as the California company gains access to numerous compounds in Galapagos’ pipeline.
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, provided an update on the progress of the development of odevixibat for pediatric cholestatic liver diseases and elobixibat for NASH.
Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH
PRESS RELEASES